UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2181-6
Program Prior Authorization/Medical Necessity
Medication Nourianz® (istradefylline)
P&T Approval Date 12/2019, 12/2020, 12/2021, 12/2022, 12/2023, 12/2024
Effective Date 3/1/2025
1. Background:
Nourianz (istradefylline) is indicated as adjunctive treatment to levodopa/carbidopa in adult
patients with Parkinson’s disease experiencing “off” episodes
Coverage will be provided for members who meet the following criteria.
2. Coverage Criteriaa:
A. Initial Authorization
1. Nourianz will be approved based on ALL of the following criteria:
a. Diagnosis of Parkinson’s disease
-AND-
b. Used as adjunctive treatment to levodopa/carbidopa in patients experiencing “off”
episodes
-AND-
c. History of failure, contraindication, or intolerance to two anti-Parkinson’s disease
therapy from the following adjunctive pharmacotherapy classes (trial must be from
two different classes):
(1) Dopamine agonists (e.g., pramipexole, ropinirole)
(2) Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
(3) Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)
Authorization will be issued for 12 months.
B. Reauthorization
1. Nourianz will be approved based on BOTH of the following criterion:
a. Documentation of positive clinical response to Nourianz therapy
-AND-
b. Patient will continue to receive treatment with a carbidopa/levodopa-containing
© 2024 UnitedHealthcare Services, Inc.
1
medication
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
4. References:
1. Nourianz [package insert]. Bedminster; NJ: Kyowa Kirin, Inc; March 2023.
2. Liang, T. Medical management of motor fluctuations and dyskinesia in Parkinson
disease. In: UpToDate, Hurtig HI (ed). UpToDate. Waltham, MA. Accessed September
2023.
3. Fox, SH, Katzenschlager, R, Lim S, et. al. International Parkinson and Movement
Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor
Symptoms of Parkinson’s Disease. Movement Disorders. 2018.
Program Prior Authorization/Medical Necessity – Nourianz (istradefylline)
Change Control
12/2019 New program
12/2020 Annual review. Updated references.
12/2021 Annual review. Updated references.
12/2022 Annual review. Updated references.
12/2023 Annual review. Updated references.
12/2024 Annual review. Updated initial authorization to 12 months.
© 2024 UnitedHealthcare Services, Inc.
2